Hangzhou Tigermed Consulting Co., Ltd. (3347.HK)
HKD 27.2
(1.68%)
HKD 27.2
(1.68%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.02 Billion CNY | 0.91% |
| 2022 | 2 Billion CNY | -30.19% |
| 2021 | 2.87 Billion CNY | 64.26% |
| 2020 | 1.74 Billion CNY | 107.9% |
| 2019 | 841.63 Million CNY | 78.24% |
| 2018 | 472.18 Million CNY | 56.86% |
| 2017 | 301.01 Million CNY | 114.01% |
| 2016 | 140.65 Million CNY | -10.0% |
| 2015 | 156.27 Million CNY | 24.53% |
| 2014 | 125.49 Million CNY | 33.43% |
| 2013 | 94.05 Million CNY | 38.83% |
| 2012 | 67.74 Million CNY | 41.76% |
| 2011 | 47.79 Million CNY | 50.72% |
| 2010 | 31.7 Million CNY | 306.48% |
| 2009 | 7.8 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 257.77 Million CNY | 9.66% |
| 2024 Q3 | 320.58 Million CNY | 24.36% |
| 2024 Q1 | 235.07 Million CNY | 61.84% |
| 2023 Q2 | 819.88 Million CNY | 44.23% |
| 2023 Q3 | 491.26 Million CNY | -40.08% |
| 2023 Q4 | 145.24 Million CNY | -70.43% |
| 2023 FY | 2.02 Billion CNY | 0.91% |
| 2023 Q1 | 568.45 Million CNY | 41.44% |
| 2022 FY | 2 Billion CNY | -30.19% |
| 2022 Q1 | 518.41 Million CNY | -52.57% |
| 2022 Q4 | 401.89 Million CNY | -2.61% |
| 2022 Q3 | 412.65 Million CNY | -38.74% |
| 2022 Q2 | 673.58 Million CNY | 29.93% |
| 2021 FY | 2.87 Billion CNY | 64.26% |
| 2021 Q1 | 455.48 Million CNY | 5.5% |
| 2021 Q2 | 799.49 Million CNY | 75.53% |
| 2021 Q3 | 526.07 Million CNY | -34.2% |
| 2021 Q4 | 1.09 Billion CNY | 107.79% |
| 2020 FY | 1.74 Billion CNY | 107.9% |
| 2020 Q2 | 743.84 Million CNY | 191.75% |
| 2020 Q3 | 319.21 Million CNY | -57.09% |
| 2020 Q1 | 254.96 Million CNY | -18.68% |
| 2020 Q4 | 431.75 Million CNY | 35.26% |
| 2019 Q2 | 206.61 Million CNY | 41.99% |
| 2019 Q4 | 313.51 Million CNY | 78.12% |
| 2019 FY | 841.63 Million CNY | 78.24% |
| 2019 Q1 | 145.5 Million CNY | -5.68% |
| 2019 Q3 | 176 Million CNY | -14.81% |
| 2018 Q3 | 99.26 Million CNY | -19.13% |
| 2018 FY | 472.18 Million CNY | 56.86% |
| 2018 Q4 | 154.26 Million CNY | 55.4% |
| 2018 Q2 | 122.74 Million CNY | 27.99% |
| 2018 Q1 | 95.9 Million CNY | -4.72% |
| 2017 Q4 | 100.65 Million CNY | 24.67% |
| 2017 FY | 301.01 Million CNY | 114.01% |
| 2017 Q1 | 43.38 Million CNY | 5.85% |
| 2017 Q2 | 76.24 Million CNY | 75.76% |
| 2017 Q3 | 80.73 Million CNY | 5.88% |
| 2016 Q4 | 40.98 Million CNY | 90.47% |
| 2016 FY | 140.65 Million CNY | -10.0% |
| 2016 Q2 | 37.94 Million CNY | -5.64% |
| 2016 Q1 | 40.2 Million CNY | -12.15% |
| 2016 Q3 | 21.51 Million CNY | -43.29% |
| 2015 Q2 | 40.04 Million CNY | 11.61% |
| 2015 Q1 | 35.87 Million CNY | -11.79% |
| 2015 FY | 156.27 Million CNY | 24.53% |
| 2015 Q3 | 34.58 Million CNY | -13.64% |
| 2015 Q4 | 45.77 Million CNY | 32.35% |
| 2014 Q2 | 27.46 Million CNY | 2.65% |
| 2014 FY | 125.49 Million CNY | 33.43% |
| 2014 Q4 | 40.67 Million CNY | 32.94% |
| 2014 Q3 | 30.59 Million CNY | 11.41% |
| 2014 Q1 | 26.75 Million CNY | 0.1% |
| 2013 Q1 | 21.92 Million CNY | 2.59% |
| 2013 Q4 | 26.73 Million CNY | 26.87% |
| 2013 FY | 94.05 Million CNY | 38.83% |
| 2013 Q3 | 21.06 Million CNY | -13.42% |
| 2013 Q2 | 24.33 Million CNY | 11.0% |
| 2012 Q4 | 21.36 Million CNY | 50.76% |
| 2012 FY | 67.74 Million CNY | 41.76% |
| 2012 Q2 | 17.35 Million CNY | 16.87% |
| 2012 Q1 | 14.84 Million CNY | -1.02% |
| 2012 Q3 | 14.17 Million CNY | -18.33% |
| 2011 Q3 | 9.94 Million CNY | 0.0% |
| 2011 FY | 47.79 Million CNY | 50.72% |
| 2011 Q4 | 15 Million CNY | 50.86% |
| 2010 FY | 31.7 Million CNY | 306.48% |
| 2009 FY | 7.8 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Life Healthcare Group Limited | 15.81 Million HKD | -12700.923% |
| China Biotech Services Holdings Limited | -95.44 Million HKD | 2221.439% |